Status:
COMPLETED
Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
Misr International University
Conditions:
Covid19
Corona Virus Infection
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Coronavirus disease 2019 (COVID-19) remains a threatening pandemic, due to its rapid transmission, uncertain risk factors for progression that lead to its lethality and yet unsatisfactory antiviral th...
Detailed Description
Recent research confirmed that levels of IL-6 seem are associated with COVID-19 induced inflammatory response, respiratory failure, needing for mechanical ventilation and/or intubation and mortality. ...
Eligibility Criteria
Inclusion
- Age 18 to 65 years.
- COVID-19 hospitalized patients with pneumonia proved by chest X-ray or CT scan.
- Confirmed infection with COVID-19 virus using RT-PCR or strongly suspected to be infected with pending confirmation studies.
- Have acute respiratory distress syndrome (ARDS).
- Having either peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg.
Exclusion
- Age greater than 85 years-old
- Creatinine clearance (CrCl) \< 10ml/min.
- Severe circulatory shock with a dose of norepinephrine higher than 1.0 μg/kg/min.
- Pregnant women.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT04739345
Start Date
December 1 2020
End Date
October 1 2022
Last Update
February 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teachers Hospital
Cairo, Please Select, Egypt, 11314